Colorectal Cancer [2017]
Will new targeted therapies transform the treatment of colorectal cancer?
Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol-Myers Squibb) represent the most recent additions to the CRC treatment armamentarium, do KOLs believe they’ll make an impact? An array of programmes are in late-stage development, including other PD-1/PD-L1 inhibitors, BRAF/MEK inhibitors, and cancer vaccines. All are vying for patients and the all-important seal of approval from key opinion leaders. But how will these products fare in a highly competitive space? And what will be the key to clinical and commercial differentiation? KOLs provide candid insights on these and other new therapies, their likely use, and how they’ll affect current mainstays such as anti-VEGFs and anti-EGFRs, in KOL Insight: Colorectal Cancer.
Ten North American and European KOLs provide their insight on 8 marketed/registered products, 7 pipeline programmes, 3 early-stage mechanisms of action and the potential for bevacizumab biosimilars.
Top takeaways
“Personally, I'm not 100 percent comfortable with that because with statistics you have to make some assumptions that things are close enough, but not exactly the same. When you say, ‘no clinically meaningful difference,’ that's in one tumour type and in one study. One study in lung cancer doesn't necessarily tell you that it's going to have the same [efficacy] in colon cancer.”US Key Opinion Leader
“From a philosophical point of view, this is an interesting strategy. But I don't see the point to go in a Phase III trial, which is very costly and very difficult to run, when the Phase II trial is negative. What is the point? You should move to another target or modify something. I have worked on colorectal cancer for 15 years more or less. I have never seen any Phase II negative trial which converted into a positive Phase III trial, never in my life. I would not bet any money on this trial.”European Key Opinion Leader
Sample of therapies covered
Marketed/Registered Therapies
KOLs from North America
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while Keytruda (pembrolizumab; Merck & Co.) and Opdivo (nivolumab; Bristol-Myers Squibb) represent the most recent additions to the CRC treatment armamentarium, do KOLs believe they’ll make an impact? An array of programmes are in late-stage development, including other PD-1/PD-L1 inhibitors, BRAF/MEK inhibitors, and cancer vaccines. All are vying for patients and the all-important seal of approval from key opinion leaders. But how will these products fare in a highly competitive space? And what will be the key to clinical and commercial differentiation? KOLs provide candid insights on these and other new therapies, their likely use, and how they’ll affect current mainstays such as anti-VEGFs and anti-EGFRs, in KOL Insight: Colorectal Cancer.
Ten North American and European KOLs provide their insight on 8 marketed/registered products, 7 pipeline programmes, 3 early-stage mechanisms of action and the potential for bevacizumab biosimilars.
Top takeaways
- It’s about to get personal. As gene mapping becomes more common in the diagnosis of CRC, what impact will this have on treatment selection and sequencing of current and future treatment options?
- Outlook unclear for checkpoint inhibitors. KOLs are split on whether these new additions will have a significant impact on CRC treatment outcomes. What could drive higher rates of adoption in the treatment algorithm?
- New treatment guidelines on the horizon? Data on left side vs. right side tumours could usher in significant changes in the treatment algorithm for CRC. Do KOLs believe treatment guidelines will evolve, and what impact will this have on treatment selection?
- Combination regimens to lead the charge. KOLs agree that combination regimens will become an increasingly important part of the CRC treatment algorithm in the near future. But which regimens are the best, and what clinical trials are needed to support their approval?
- KOLs warming to bevacizumab biosimilars, but concerns still remain. With over a dozen Avastin biosimilars on the way, and one already approved in the US, KOLs are cautiously optimistic. What are their concerns, and what will biosimilars have to show to achieve widespread uptake?
- The bar has been set, and it’s high. KOLs believe that novel therapies for CRC will be held to higher safety and efficacy standards in the future. How will this impact clinical development and investment in an area which still has significant levels of unmet need?
“Personally, I'm not 100 percent comfortable with that because with statistics you have to make some assumptions that things are close enough, but not exactly the same. When you say, ‘no clinically meaningful difference,’ that's in one tumour type and in one study. One study in lung cancer doesn't necessarily tell you that it's going to have the same [efficacy] in colon cancer.”US Key Opinion Leader
“From a philosophical point of view, this is an interesting strategy. But I don't see the point to go in a Phase III trial, which is very costly and very difficult to run, when the Phase II trial is negative. What is the point? You should move to another target or modify something. I have worked on colorectal cancer for 15 years more or less. I have never seen any Phase II negative trial which converted into a positive Phase III trial, never in my life. I would not bet any money on this trial.”European Key Opinion Leader
Sample of therapies covered
Marketed/Registered Therapies
- Aflibercept (Zaltrap; Regeneron/Sanofi)
- Bevacizumab (Avastin; Roche)
- Ramucirumab (Cyramza; Eli Lilly)
- Cetuximab (Erbitux; Eli Lilly/Merck Group)
- Panitumumab (Vectibix; Amgen)
- Regorafenib (Stivarga; Bayer)
- Nivolumab (Opdivo; BMS)
- Pembrolizumab (Keytruda; Merck & Co.)
- Atezolizumab (Tecentriq; Roche)
- Lefitolimod (Mologen)
- Binimetinib (Array Biopharma/Pierre Fabre)
- Cobimetinib (Cotellic; Exelixis)
- Nintedanib (Boehringer Ingelheim)
- Napabucasin (Boston Biomedical/Sumitomo Dainippon Pharma)
- OncoVAX (Vaccinogen)
- Veliparib (ABT-888; AbbVie)
- Entinostat (Syndax Pharmaceuticals)
- SYM004 (futuximab/modotuximab; Symphogen)
KOLs from North America
- Johanna Bendell. Director of GI Cancer Research Program at Sarah Cannon Research Institute, Nashville, TN
- Thomas Cartwright. Co-Chairman US Oncology Gastrointestinal Research, Ocala, FL
- Mike Morse. Professor of Medicine, Professor in the Department of Surgery, Member of the Duke Cancer Institute, Duke University School of Medicine, Durham, NC
- Bert O’Neil. Joseph W. and Jackie J. Cusick Professor of Oncology, Indiana University of Medicine, Indianapolis, IN
- Bassel el-Rayes. Chief Clinical Research Scientist, Winship Cancer Institute, Emory University Hospital and Grady Memorial Hospital, Atlanta, GA
- Guiseppe Aprille. Department of Oncology, University Hospital, Udine, Italy
- Khurum Khan. Locum Consultant GI and Acute Oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK
- Jaafar Bennouna. Professor, Medical Oncology, University of Nantes, France and Institut de Cancérologie de l’Ouest, Nantes, France
- John Bridgewater. Clinical Researcher, University College London Cancer Institute, London, UK
- Anonymous German KOL. Head of Oncology/Haematology Department, large teaching hospital in Germany
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Money Back Guarantee
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. EXECUTIVE SUMMARY
2. RESEARCH OBJECTIVES AND FOCUS
2.1 Research objectives
2.2 Research focus
3. OVERVIEW OF CURRENT SYSTEMIC THERAPIES IN COLORECTAL CANCER
3.1 VEGF inhibitors
3.1.1 Key insights summary
3.1.2 Avastin (bevacizumab; Genentech/Roche/Chugai)
3.1.3 Zaltrap (ziv-aflibercept; Regeneron/Bayer Healthcare/Sanofi)
3.1.4 Cyramza (ramucirumab; Eli Lilly)
3.2 EGFR Inhibitors
3.2.1 Key insights summary
3.2.2 Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck Group)
3.2.3 Vectibix (panitumumab; Amgen/Takeda)
3.3 Multi-target therapies
3.3.1 Key insights summary
3.3.2 Stivarga (regorafenib; Bayer Healthcare)
3.4 Immune checkpoint inhibitors
3.4.1 Key insights summary
3.4.2 Keytruda (pembrolizumab; Merck and Co.)
3.5 Key insights summary
3.5.1 Opdivo (nivolumab; Bristol-Myers Squibb)
3.6 Position of biosimilars in CRC treatment paradigm
3.6.1 Key insights summary
3.7 Reflections on current treatment paradigm
3.7.1 Key insights summary
4. SELECTED LATE-STAGE PIPELINE PROGRAMMES
4.1 Tecentriq (atezolizumab; Roche)
4.1.1 Key insights summary
4.2 Lefitolimod (Mologen)
4.2.1 Key insights summary
4.3 MEK/BRAF inhibitors
4.3.1 Overview
4.3.2 Key insights summary
4.4 Nintedanib (Boehringer Ingelheim)
4.4.1 Key insights summary
4.5 Napabucasin (Boston Biomedical/Sumitomo Dainippon Pharma)
4.5.1 Key insights summary
4.6 OncoVAX (colorectal cancer vaccine; Vaccinogen)
4.6.1 Key insights summary
5. EARLY- TO MID-STAGE PIPELINE PROGRAMMES
5.1 Key insights summary
5.2 Sym004 (futuximab/modotuximab; Symphogen)
5.3 Veliparib (ABT-888; AbbVie)
5.4 Entinostat (Syndax Pharmaceuticals)
6. EVOLUTION OF THE CRC TREATMENT LANDSCAPE
6.1 Key insights summary
7. APPENDIX
7.1 KOL detail
7.1.1 US KOLs
7.1.2 European Key Opinion Leaders
2. RESEARCH OBJECTIVES AND FOCUS
2.1 Research objectives
2.2 Research focus
3. OVERVIEW OF CURRENT SYSTEMIC THERAPIES IN COLORECTAL CANCER
3.1 VEGF inhibitors
3.1.1 Key insights summary
3.1.2 Avastin (bevacizumab; Genentech/Roche/Chugai)
3.1.3 Zaltrap (ziv-aflibercept; Regeneron/Bayer Healthcare/Sanofi)
3.1.4 Cyramza (ramucirumab; Eli Lilly)
3.2 EGFR Inhibitors
3.2.1 Key insights summary
3.2.2 Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck Group)
3.2.3 Vectibix (panitumumab; Amgen/Takeda)
3.3 Multi-target therapies
3.3.1 Key insights summary
3.3.2 Stivarga (regorafenib; Bayer Healthcare)
3.4 Immune checkpoint inhibitors
3.4.1 Key insights summary
3.4.2 Keytruda (pembrolizumab; Merck and Co.)
3.5 Key insights summary
3.5.1 Opdivo (nivolumab; Bristol-Myers Squibb)
3.6 Position of biosimilars in CRC treatment paradigm
3.6.1 Key insights summary
3.7 Reflections on current treatment paradigm
3.7.1 Key insights summary
4. SELECTED LATE-STAGE PIPELINE PROGRAMMES
4.1 Tecentriq (atezolizumab; Roche)
4.1.1 Key insights summary
4.2 Lefitolimod (Mologen)
4.2.1 Key insights summary
4.3 MEK/BRAF inhibitors
4.3.1 Overview
4.3.2 Key insights summary
4.4 Nintedanib (Boehringer Ingelheim)
4.4.1 Key insights summary
4.5 Napabucasin (Boston Biomedical/Sumitomo Dainippon Pharma)
4.5.1 Key insights summary
4.6 OncoVAX (colorectal cancer vaccine; Vaccinogen)
4.6.1 Key insights summary
5. EARLY- TO MID-STAGE PIPELINE PROGRAMMES
5.1 Key insights summary
5.2 Sym004 (futuximab/modotuximab; Symphogen)
5.3 Veliparib (ABT-888; AbbVie)
5.4 Entinostat (Syndax Pharmaceuticals)
6. EVOLUTION OF THE CRC TREATMENT LANDSCAPE
6.1 Key insights summary
7. APPENDIX
7.1 KOL detail
7.1.1 US KOLs
7.1.2 European Key Opinion Leaders
